Azithromycin for acute lower respiratory tract infections (Q24242162)

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Etiology and treatment of community-acquired pneumonia in ambulatory children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Azithromycin versus comparative therapy for the treatment of community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Confronting drug-resistant pneumococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Epidemiology of lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Etiology of community-acquired pneumonia in out-patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Serological investigation of pneumonia as it presents to the physician's office

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Role of oral antibiotics in treatment of community-acquired lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Antibiotics for pneumonia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Quality of Care, Process, and Outcomes in Elderly Patients With Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Use of investigations in lower respiratory tract infection in the community: a European survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Azithromycin for acute lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

Community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

The value of routine microbial investigation in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

Clinical efficacy of azithromycin in lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children. The Paediatric Azithromycin Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021

ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001954.PUB3

7 January 2021